DNB Asset Management AS Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE

DNB Asset Management AS grew its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 6.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 249,081 shares of the biopharmaceutical company’s stock after purchasing an additional 14,924 shares during the quarter. DNB Asset Management AS’s holdings in Xenon Pharmaceuticals were worth $10,001,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. Marshall Wace LLP boosted its stake in Xenon Pharmaceuticals by 34.6% in the second quarter. Marshall Wace LLP now owns 1,020,254 shares of the biopharmaceutical company’s stock valued at $31,934,000 after acquiring an additional 262,109 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Xenon Pharmaceuticals by 11.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company’s stock valued at $56,171,000 after buying an additional 142,452 shares during the last quarter. American Century Companies Inc. purchased a new position in shares of Xenon Pharmaceuticals during the 2nd quarter valued at $21,280,000. Saturn V Capital Management LP grew its stake in shares of Xenon Pharmaceuticals by 13.2% during the 2nd quarter. Saturn V Capital Management LP now owns 468,364 shares of the biopharmaceutical company’s stock worth $14,660,000 after acquiring an additional 54,653 shares during the period. Finally, Aberdeen Group plc increased its holdings in Xenon Pharmaceuticals by 11.1% in the 3rd quarter. Aberdeen Group plc now owns 579,145 shares of the biopharmaceutical company’s stock worth $23,253,000 after acquiring an additional 57,653 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors.

More Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Two analyst upgrades lift sentiment — Needham raised its price target to $58 with a Buy rating and Wells Fargo nudged its target to $49 with an Overweight rating, implying meaningful upside from current levels, which supports longer-term investor interest. Analyst Price Target Raises (Benzinga)
• Positive Sentiment: Company update highlights near-term clinical catalysts and strong pro forma cash runway — Xenon reiterated a Phase 3 topline readout for azetukalner (X-TOLE2) expected in early March and reported pro forma cash (~$716M) that management says extends runway into H2 2027, reducing near-term financing risk and keeping the pipeline-funded. Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst/press commentary stresses pipeline focus despite higher R&D — Coverage (e.g., Zacks) notes a wider Q4 loss driven by a 47% jump in R&D spend but underscores ongoing late‑stage azetukalner trials and early-stage pain programs; useful context but not an immediate stock mover beyond the earnings reaction. Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus
• Negative Sentiment: Refreshed $400M at-the-market (ATM) equity program — Xenon filed to refresh an ATM capacity, which increases the potential for share issuance. While it provides financing optionality, investors often view ATM refreshes as a near-term dilution risk that can pressure the stock. Xenon Pharmaceuticals Refreshes $400 Million ATM Equity Program
• Negative Sentiment: Q4 EPS missed estimates — Xenon reported ($1.31) EPS vs. consensus ($1.20), a larger loss year-over-year; the miss likely contributed to intra-day selling despite the pipeline updates. Xenon Reports Q4 and Full Year 2025 Financial Results (Press Release PDF)

Insider Transactions at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 40,000 shares of Xenon Pharmaceuticals stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the completion of the sale, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at approximately $266,580. The trade was a 86.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 65,205 shares of company stock worth $2,919,762 in the last three months. Insiders own 4.07% of the company’s stock.

Xenon Pharmaceuticals Stock Down 3.8%

Xenon Pharmaceuticals stock opened at $43.23 on Friday. The stock has a market cap of $3.34 billion, a price-to-earnings ratio of -9.92 and a beta of 0.96. The business has a 50-day simple moving average of $42.49 and a 200 day simple moving average of $41.04. Xenon Pharmaceuticals Inc. has a 52 week low of $26.74 and a 52 week high of $46.99.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.11). During the same quarter in the previous year, the company posted ($0.84) earnings per share. On average, research analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Wall Street Analyst Weigh In

XENE has been the topic of several recent research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $55.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, November 4th. Wolfe Research assumed coverage on shares of Xenon Pharmaceuticals in a research note on Monday, February 23rd. They set an “outperform” rating and a $60.00 price target on the stock. Stifel Nicolaus set a $66.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, February 10th. JPMorgan Chase & Co. boosted their target price on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Finally, Wells Fargo & Company increased their target price on Xenon Pharmaceuticals from $48.00 to $49.00 and gave the stock an “overweight” rating in a research report on Friday. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $55.50.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.